HCW Biologics 株価情報 (NASDAQ: HCWB)

最新ニュース HCW Biologics (NASDAQ:HCWB) 株価情報

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

Raymond James analyst Olivia Tong maintains e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) with a Strong Buy and raises the price target from $105 to $130.

News

Price Target

Analyst Ratings

Raymond James Maintains Strong Buy on e.l.f. Beauty, Raises Price Target to $130

Raymond James analyst John Freeman maintains EOG Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EOG#NYSE">EOG</a>) with a Strong Buy and raises the price target from $148 to $158.

Raymond James Maintains Strong Buy on EOG Resources, Raises Price Target to $158

FORM

FormFactor Purchases Manufacturing Site In Farmers Branch, Texas For $55M

Dow Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOW#NYSE">DOW</a>) disclosed the signing of a sale and purchase agreement to divest its 50% stake in DowAksa Advanced Composites Holdings BV to its joint venture partner, Aksa Akrilik Kimya Sanayii A.Ş, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/n45717940/dow-announces-agreement-to-sell-its-50-ownership-in-dowaksa-joint-venture" rel="noreferrer noopener">for about $125 million</a>.
The proceeds imply an enterprise value of around 10 times the projected operating EBITDA for 2025 after factoring in debt.
With this transaction, Aksa will become the sole owner of DowAksa.
Also Read: <a href="https://www.benzinga.com/25/04/44824289/dow-downgraded-analyst-sees-dividend-risk-trade-war-concerns-a-major-headwind" target="_blank" rel="noreferrer noopener">Dow Downgraded: Analyst Blames &#8216;Perfect Storm&#8217; Of Weak Macro, High Costs, Trade Barriers</a>
Dow's decision to exit the joint venture, established in 2012, aligns with its "best-owner mindset" strategy, which emphasizes concentrating on core, high-value downstream operations.
The proceeds from the sale will contribute to the company's balanced approach to capital allocation.
The transaction is anticipated to close in the third quarter of 2025, pending standard regulatory approvals and closing conditions.
In April, the company reported that first-quarter 2025 sales declined 3% year over year to $10.431 billion. It beat the consensus of $10.24 billion, and adjusted EPS came in at 2 cents, beating the <a href="https://www.benzinga.com/25/04/44978321/dow-posts-surprise-profit-as-volumes-rise-in-q1-but-cash-flow-and-capex-outlook-signal-market-caution" target="_blank" rel="noreferrer noopener">consensus estimate of a 1 cent loss</a>.
Investors can gain exposure to the stock via&nbsp;Amplify ETF Trust Amplify Natural Resources Dividend Income ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NDIV#NYSE">NDIV</a>) and Invesco S&amp;P 500 High Dividend Low Volatility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPHD#NYSE">SPHD</a>).
Price Action: DOW shares are down 0.14% at $27.70 premarket at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/45020055/analyst-upgrades-dow-calls-capex-cut-and-asset-sales-positive" target="_blank" rel="noreferrer noopener">Analyst Upgrades Dow, Calls Capex Cut And Asset Sales Positive</a></li>
</ul>

Asset Sales

NDIV

SPHD

Dow Exits DowAksa JV, Stays Course On 'Best-Owner' Strategy

ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), today announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at a price of $6.65 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about June&nbsp;3, 2025, subject to the satisfaction of customary closing conditions.
Cantor and Canaccord Genuity acted as joint book-running managers for the offering.
The net proceeds of this offering are expected to be used for general corporate purposes, including working capital, operating expenses, and capital expenditures, as well as funding the disbursement to Renergen under our bridge loan agreement with Renergen.

Offerings

ASPI

ASP Isotopes Prices $50M Underwritten Registered Direct Offering Of 7.5M Shares At $6.65 Each To Institutional Investor

<ul>
<li>TSLA</li>
<li>GLD</li>
<li>UNH</li>
<li>NVDA</li>
<li>GOOGL</li>
<li>GOOG</li>
<li>CLF</li>
<li>PLTR</li>
<li>BULL</li>
<li>RDDT</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

Trading Ideas

BULL

GOOG

GOOGL

NVDA

PLTR

RDDT

TSLA

Top 10 Trending Stocks On WallStreetBets As Of June 2, 2025 (Via Swaggy Stocks)

Raymond James analyst John Davis maintains Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) with a Outperform and raises the price target from $74 to $79.

Raymond James Maintains Outperform on Block, Raises Price Target to $79

Buyer's remorse is just beginning, warns former Make America Great Again insider Rich Logis, who sees an economic hangover ahead for households still filling carts under rising tariff-driven prices.
Inflation jitters, a souring confidence gauge and a ballooning deficit all point in the same direction. In a May 11 opinion piece for <a href="https://www.salon.com/2025/05/11/we-should-welcome-maga-remorse-i-should-know--it-saved-me/">Salon</a>, Logis, the executive director of the nonprofit Leaving MAGA, <a href="https://www.salon.com/2025/05/11/we-should-welcome-maga-remorse-i-should-know--it-saved-me/">&nbsp;argues</a> that the costs of MAGA are landing squarely on lower- and middle-income wallets that once celebrated them.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Logis recounted how rallies became "all-consuming" until looming deportations, <a href="https://www.benzinga.com/25/05/45447473/trump-says-tariff-money-could-replace-the-income-tax-april-customs-collections-hit-record-15-4-billion-as-new-duties-take-effect">tariff threats</a> and constitutional flashpoints forced him to step away from the movement and launch the nonprofit Leaving MAGA.&nbsp;
<h2 class="wp-block-heading">Reality Checks Pile Up</h2>
Fresh polling backs his gut feeling. A nationwide April 23 survey by the<a href="https://www.pewresearch.org/politics/2025/04/23/trumps-job-rating-drops-key-policies-draw-majority-disapproval-as-he-nears-100-days/"> Pew Research Center</a> found President Donald Trump's job approval stalled at 40%, while 59% of adults rejected his sweeping tariff hikes—seven points worse than February.&nbsp;
Washington's ledger looks no rosier. The nonpartisan<a href="https://www.cbo.gov/publication/60870"> Congressional Budget Office</a> projected in January that the federal deficit will hit $1.9 trillion this year, pushing government debt toward 118% of GDP in 2035.
Trending: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Immigration policy adds another bill. A March brief from the<a href="https://www.migrationpolicy.org/article/trump-immigration-mass-deportation-priority"> Migration Policy Institute</a> estimated stepped-up deportations—and the public-relations blitz selling them—will cost at least $200 million before court fights or transport fees.&nbsp;
Retailers are speaking out. Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) CFO John David Rainey said in a May 15 <a href="https://corporate.walmart.com/content/dam/corporate/documents/newsroom/2025/05/15/walmart-releases-q1-fy26-earnings/q1-fy26-earnings-call-transcript.pdf">earnings call</a> that inflation is still a factor—up about 40 basis points from last year—but the company is managing it through stronger margins and a shift in its business mix, giving it some room to adjust prices if needed.
Atlanta <a href="https://www.benzinga.com/news/25/02/43788384/fed-chair-powell-stands-firm-standard-case-for-free-trade-logically-still-makes-sense-amid-trumps-import-taxes">Federal Reserve</a> President Raphael Bostic warned that businesses are nearing the limits of their ability to absorb import taxes, suggesting a broad price spike could be on the horizon, <a href="https://www.reuters.com/business/us-economy-may-be-brink-price-hike-wave-feds-bostic-says-2025-05-20/">Reuters reported.</a> He said that earlier tactics like stockpiling are becoming less effective, and future price shifts may reveal how consumers respond.
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.
Consumer mood already reflects the sticker shock. The University of Michigan's preliminary May <a href="https://www.sca.isr.umich.edu/">consumer sentiment index</a> slid to 50.8—its lowest reading since 2022—as nearly three-quarters of respondents spontaneously blamed tariffs, according to the survey.&nbsp;
Against that backdrop, Logis offers five guideposts for relatives hoping to ease MAGA supporters off the ride: find common ground, skip insults, invite reconciliation, keep conversations respectful and, only after trust builds, introduce stories of other defectors.&nbsp;
Calling MAGA a cult or crowing "I told you so" fuels defensiveness, he said.
Logis believes empathy plus stark wallet math will do the heavy lifting. "There will be a gradual, and then sudden, realization," he wrote, that tariffs, deportations and runaway deficits "will harm lower-income and middle-class Americans, along with small-business owners, worst of all."&nbsp;
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
Image: Shutterstock

Personal Finance

'Buyer's Remorse Is Just Beginning,' Says Ex-MAGA Activist Rich Logis — Predicts Economic Fallout For Trump's Supporters

Brookfield Residential Forms Strategic JV With Trez Capital To Develop New Master-Planned Community In Central Florida Named Osprey Creek

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs analyst Robert Cox initiated coverage on Aspen Insurance Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Neutral rating and announced a price target of $38. Aspen Insurance shares closed at $34.30 on Friday. <a href="https://www.benzinga.com/quote/ahl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. analyst Brandon Folkes initiated coverage on Cardiol Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDL#NASDAQ">CRDL</a>) with a Buy rating and announced a price target of $9. Cardiol Therapeutics shares closed at $1.4251 on Friday. <a href="https://www.benzinga.com/quote/crdl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Christopher Carril initiated coverage on Shake Shack Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) with a Sector Weight rating. Shake Shack shares closed at $129.79 on Friday. <a href="https://www.benzinga.com/quote/shak/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Matthew Coad initiated coverage on Visa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Buy rating and announced a price target of $400. Visa shares closed at $365.19 on Friday. <a href="https://www.benzinga.com/quote/v/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Patrick Cunningham initiated coverage on RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) with a Buy rating and announced a price target of $135. RPM shares closed at $113.84 on Friday. <a href="https://www.benzinga.com/quote/rpm/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying Visa stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02091105/image-9-1024x584.png" alt="" class="wp-image-935200" style="width:617px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02091105/image-9-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02091105/image-9-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02091105/image-9-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02091105/image-9.png 1135w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

Initiation

Pre-Market Outlook

Markets

CRDL

SHAK

This Visa Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

GE Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is passing along higher prices to customers after U.S. trade tariffs created a $500 million cost burden, meaning airlines, and eventually passengers, will soon <a href="https://www.benzinga.com/topic/tariffs">feel the heat.</a>
Speaking from New Delhi at the International Air Transport Association's annual meeting, chief executive officer Larry Culp told Bloomberg that the world's largest aircraft engine maker is no longer able to shield customers from the financial impact of trade restrictions introduced under President Donald Trump's policies.
"We will be taking cost actions and passing along some of that residual," Culp said.
<h3 class="wp-block-heading">Is GE Already Seeing The Tariff Impact?</h3>
"Very much so," Culp said when asked whether the tariffs are affecting business now. The company has seen rising expenses and is adjusting its pricing strategy to preserve margins.
"We're managing the best we can, mitigating where we can through those supply-chain improvements but also through the cost and price actions," he said.
<h3 class="wp-block-heading">Tariff-Free Trade Helped Build US Aerospace</h3>
For decades, the global aerospace industry benefited from the 1979 Civil Aviation Agreement, which allowed for duty-free trade among key nations. 
Culp said that the framework helped U.S. companies like GE and Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) build a $75 billion annual trade surplus in aviation. But that advantage is eroding under new trade barriers.
"We've been advocating for a return to where we were on the heels of that 1979 civil aviation agreement," he said.
The U.S. has already signed a trade deal with the U.K., and more negotiations are underway. 
"I think June will be an important month," Culp added, as more agreements could shape the future cost landscape for aerospace exports.
<h3 class="wp-block-heading">Production Pressure Grows As Airbus And Boeing Ramp Up</h3>
GE is working to keep pace with increasing production from both Airbus SE and Boeing Co., who are planning record monthly output levels. 
"Be it with Airbus, be it with Boeing, they are effectively sold out through the rest of this decade," Culp said.
GE holds a $170 billion backlog and expects to build more engines in the second half of 2025 and in 2026 than in the first half of this year. 
Culp said parts received from key suppliers in April and May rose double-digits compared to the first quarter, a sign that the company's supply chain efforts are starting to pay off.
GE is also a major supplier to the U.S. Department of Defense, powering two-thirds of the U.S. combat aircraft and helicopters. Culp said the company remains focused on long-term military contracts and advanced engine development as defense spending increases.
When asked about growing concern over technology exports to China, Culp said GE has followed strict government procedures for years and is prepared for tighter controls if they come. 
"We welcome the scrutiny," he said.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/06/45715850/trump-administration-silently-employs-palantir-to-gather-personal-data-of-each-american-raising-privacy-data-misuse-concerns-report">Trump Administration Silently Employs Palantir To Gather Personal Data Of Each American, Raising Privacy, Data Misuse Concerns: Report</a></li>
</ul>
Photo: Shutterstock

Get Ready To Pay The Price Of Tariffs: GE Is Already Passing Costs To Customers

Wedbush analyst David Nierengarten downgrades Blueprint Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPMC#NASDAQ">BPMC</a>) from Outperform to Neutral and raises the price target from $128 to $129.

Downgrades

BPMC

Wedbush Downgrades Blueprint Medicines to Neutral, Raises Price Target to $129

Contracts

Diana Shipping Inc. Secures Time Charter Contract For Newcastlemax Vessel m/v Newport News At $25,000 Per Day With Bohai Ocean Shipping Through June To October 2026, Projecting ~$10.95M Gross Revenue For Minimum Charter Period

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">82.76</td>
<td align="right">1.23</td>
<td align="right">1.50</td>
<td>81.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">86.85</td>
<td align="right">0.51</td>
<td align="right">0.59</td>
<td>8.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.71</td>
<td align="right">0.07</td>
<td align="right">0.05</td>
<td>4.5K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">100.77</td>
<td align="right">-0.63</td>
<td align="right">-0.63</td>
<td>4.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">50.71</td>
<td align="right">-0.25</td>
<td align="right">-0.50</td>
<td>151.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.57</td>
<td align="right">-0.16</td>
<td align="right">-0.39</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">230.02</td>
<td align="right">-0.89</td>
<td align="right">-0.39</td>
<td>13.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">142.30</td>
<td align="right">-0.52</td>
<td align="right">-0.37</td>
<td>2.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">213.04</td>
<td align="right">-0.76</td>
<td align="right">-0.36</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.69</td>
<td align="right">-0.23</td>
<td align="right">-0.29</td>
<td>10.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.70</td>
<td align="right">-0.13</td>
<td align="right">-0.16</td>
<td>5.0K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 2, 2025

CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of&nbsp; engineered T cell therapeutics that deploy phagocytic (i.e., target-cell eating) mechanisms alongside the array of built-in target cell destroying&nbsp; mechanisms used by T cells, announces two previously announced U.S. patent applications have been granted by the U.S. Patent and Trademark Office (USPTO), and one European patent application has been allowed by &nbsp;the European Patent Office, all of which significantly expand the Company's intellectual property portfolio.

CERO

CERo Therapeutics Secures Key U.S. And European Patents For Next-Gen T Cell Therapies

Mizuho analyst Maheep Mandloi maintains Sunrun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) with a Outperform and lowers the price target from $16 to $13.

Mizuho Maintains Outperform on Sunrun, Lowers Price Target to $13

<a href="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai" title="https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai">https://www.theinformation.com/articles/alibaba-helped-china-take-lead-u-s-open-source-ai</a>

BABA

'How Alibaba Helped China Take the Lead From the U.S. in Open-Source AI' - The Information

CETX

Cemtrex's Vicon Receives $0.8M Contracts From U.K. Correctional Facilities

Artelo Biosciences, Inc. (NASDAQ:<a href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today welcomed the publication of a comprehensive review in Neurobiology of Disease, titled "<a href="https://www.globenewswire.com/Tracker?data=B-RN4N7zHYvKUcdnjlk4jtgfVTPS2vdvJO8iwTfiBBQKgcGy73ar6qKxYKUSQGCyhZlU8iU25vJPDpq-Py27VtL8RMaAeAYYH8VDAoQflHL4J3VgRcOg3S3xvZuFl_zErpFmLBusrqy1dx8nVX7TT26x5aRVrFfN3s48dpx1OHoJvAKl6ec0x76h0rkWNwg1ACmHbWI3Rei8CuA4sof5mWssyBPzpfRSLwkvjI2YsOzPjG7KCdv2nEzTG64q_qRbp6dw9BQA2KOU7R0B2et_Mv32ywfx5dyEHK3CzMVpbRxeeO15huBs6bT7oLzU3piEkCqWeOINLkOq956W9SisJUwSrWtTWRwmTyETP7w185JpH0Nkl4zV1l76j62-WrmuRp1bEuHANGZtJPKblL_GURjd2rdCPGhqW4HxQ-I0bS-Hj6jzqt1akX3PXcckl42Km8-RghXycIO7tACZHaEbWGubp2h2wxvkDS7cr0LFcIXcIQOXKQUgYnre5osm0liUtN7CYOkL3q3lAOlJ5gV6ktumZ_7ZRVBP3ghWQ02OJ83xfX2ybud5XrLg7Chpe6bauNL76O0UmAqm4AetGCX98xMcmVIDc1QI10GCwCq80KJz3TPSm0bwNVimcvG0HcQGXddY1Vd6CzichWAPGs3WkEKwJY5pKFFQmg_1CMjQVaXAWc_VbUV7LEzasTQD44b-12jfW37MIlcnQm8VeXyXTo-vTsQxWj0jIWmFGQopKPwHB5FS4Y75kLeAhnBxhD9Du8AAlpfsbzes2iNbPqHuo15jHsd2wrS48QajBft3aDXKmdKyPYTsRfoZcMAjcfpYDZX5h2TsHaOJ7AfKcywPtahZaFYTTbKq3fmHvoVUZuvTBxLE-dQVXtOoupqQtQMpQ3-GAtRErvTO0pNQUKAt-1s-JcHUIfjMww815oeTB_9tpiOQ4SZK-VSfG4wx72Id6J5Mp0z0VwkYtcaL0TqVKETDao4ezhfrV4vqpZ4wSAVDVIL5hBAkNDLZsbbq10iV6EZRSltD0gWTQW-mHeDCXshBp8oce7BkAGtoPpYyesoDAoOwofiVeBFIrcwx_rz3wB3UWN4-C09cD4WtObDHYkKzecAXO9ZWnJN2aCCjRTzq3GVTUrY51fUyYpgXKxILjgsdOJxgaTVFAucXh435z-d3mxAzNvNUkxKeBWhpVy3wa_YF0Jgb5LyOb7mmPRv-fRnPuOZbpZTxvaSTnNucMSHKV1m0WCwJJb_8Y4QYMBClpw_vK25nbysSVICSUTtv73_cNxBzUpA6SUsnGV-VyYs55xZF3SuqQgO4849OgHJm1utK1f_q6RuPRx6_-l8vzWPDhkmArnkee6iLlzbRJPzfFEj7Nev9vGZbBRmv6iwwkRihobf85fwS1DpwzUa_5S97iZHM7d2377H9nCe3OCBAYhgm-qtut3cB4FGw7r4gzHDEbOYPiWSh2zEj92h1Y8jxKY73PopD1aqcvUxEEkNvXuXG2JxC3E_IDY6yJCs61DAgDcU0EcXdgQlsApTP4s9nIQ74zhE4yCJxxmV7xURXVjC8V75mvN60Gf_uXW4qCLhgqNbJNq5LI3fi20Y7jzBKScqNscKx7WqENT6qU8xzo3EAVpuiHbYUQf_aqjC5TytUmazd7338gB_iOy1qVXxXc5EJLXbFjQ2zO443ypPIsFpQGLy2gsMnGzVyUiJ5UIcP2F04BMjaU2uwn9wKyX_BI50sdQNvOwW5rtLRKQw-CCCxYDZCSCRMZGikoGiVs9ahpLrRVYV6MrIe_It9Iy8yWQnASweTB8LKKljy0kdJY08jEUyp768owoVyBj_3JYabbE21Qb6ANI_Cf7ZKZPqNpf1rjCvsuErctjj3UYXVyFvYFBOZHEDq7r4dcmgmc8Jp36KPwAjQw9Dj1tI2HYxWQbvxAtipMoPwLnAMKRob7JwQfdnrwYjLLVbtG_j_CRQ4AgfHj2YQUgmoQDh1EYKeq0ceogsacnxmsPUM9X0VSpFzuRkW2EjA7FEXxxvfkEdGpGAoxlRYejYmU8ctJs__2r_sTlx1pMzaWpa-xYNEhjS5wy6mFe22lgCBKx6UdecX_FwaE3ohf9U9RgXk7eaI2jhmPlQiXNUeNTfM_Tq8hp5y1KlF64sPwg0N6m-8oYIRIjKx3vTr5ulOhlefIcKI6C525fTw8etoHJQs5wd7I9apqcw1RkUqHns_j85Jxvx2Nl3-CQoqLmmfiDqV22UiwjSDNF5rckmM4eayMElC4dmUoTTMQ3k56Q-hIb2Qa9vXQoRpSowCSs0SMLn5GM3_RJUDl_aixjxD2YQjavah63li0pVrRzrY1rDrONeVL8eVoQMcQplvUhTpWF-SwVBwJ9BoeAwSCxV0YdJa6x-SzXKQHGXwKMMdU5b4KmX1rAvFlog5MaEmKUQOrZkA5uQt30UenpGnd5kdbJYj3w0M7xHesA-k6_1pWottxahsRm9NwT1JC8kBKt_t2Zorkd2SdycTxQIdNDHu2tTddktCiS0vCtlFrA8LvVi6s3Pd1_kOKdp6Xkf9LkxoFroY9WHxa0sVbmcDkKtfVOzjlIq78skeN0tx_mIJyYrsr6g1oOFRjc7tHgj42nmK25w5qem2orvWwv83boISDW1CmRRh6-A06f_5g4sGIn1Zz3tWKbuI9O1l3FRre4HoQCn_miaFoNKbmLCh-_1bmfrH30ClrIyby7xe6uW65cfcON1XA-7mnvtPAwSuSySbKsa0h0DW6PXkF3V0AaJUYflTQ9YWERjMAH9qMVODCUDOW3CCJB0xRgzmbqKvTuuHp00su6JUkTKCst39-HAvJpuKsAleAkvlwZZ7-Fs0s1IMH4Ufu433dKoXQWCJhOQx2-06aa5ogdCt-f8rYA8JU_NZ3Km5TKJTEIACMzkhew4OR_3IgskJd-v7LsRpCK5X9CftLsRmrluOfS3XObAIgI5NIYd4kvuWw-CrVeWApCbUD4rpoGpqgyO1Z-XvdgLAXFjjLwsKktuokSUUSEM0TwqrvdKGmxdtlq4yl8OP78pERag=">Fatty acid binding proteins and their involvement in anxiety and mood disorders</a>," that underscores the therapeutic potential of Fatty Acid Binding Protein (FABP) inhibitors in treating mood and anxiety disorders.
The peer-reviewed article was co-authored by Doctor Steven Laviolette, Professor in the Schulich School of Medicine along with other researchers from the University of Western Ontario, Canada, details extensive preclinical evidence supporting FABP5, FABP3, and FABP7 as key regulators of lipid trafficking, neuroinflammatory signaling, and endocannabinoid tone — mechanisms critically involved in the pathophysiology of anxiety and depression.

Biotech

General

ARTL

Artelo Biosciences Welcomes Publication Of Peer-Reviewed Review Highlighting Therapeutic Potential Of Fatty Acid Binding Protein Inhibitors In Treating Anxiety And Mood Disorders, Underscoring Key Roles Of FABP5, FABP3, And FABP7 In Neuroinflammation And Endocannabinoid Regulation

Mizuho analyst Maheep Mandloi maintains SolarEdge Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) with a Neutral and raises the price target from $15 to $18.

SEDG

Mizuho Maintains Neutral on SolarEdge Technologies, Raises Price Target to $18

IPOs

Press Releases

HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules

HCW Biologics Inc. Received NASDAQ Staff Determination Letter

HCW Biologics' Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

Comments

HCW Biologics

ニュース

最新ニュース HCW Biologics (NASDAQ:HCWB) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル